Tagged with S

Czech Republic Ladislav Drož, CEO of APIGENEX, reveals the company’s strategy to survive after a leadership change and a reshuffling of the small-molecule science operations at their main client, Novo Nordisk. Drož also discusses APIGENEX’s future goals of investing in robotics and automation. APIGENEX’s services include chemistry, experimental pharmacology, clinical pharmacology, registration…

UAE The Pharmaceutical Research and Manufacturers Association Gulf (PHRMAG) represents the region’s leading innovative biopharmaceutical research companies. Dream Samir, secretary general of the organization, discusses PHRMAG’s efforts to continue impacting the region’s pharmaceutical industry, the priorities of the private sector and why the UAE is well positioned to compete on the…

Czech Republic Patrik Reichl, CEO of CzechInvest, the Investment and Business Development Agency under the Ministry of Industry and Trade of the Czech Republic, breaks down the role of the agency in implementing the Innovation Strategy 2019–2030 and transforming the Czech Republic as the “Country for the Future” by fostering a local…

Belgium Joris Van Assche, managing director of the Belgian association for accessible medicines, Medaxes, highlights the need for a stronger policy to create a more positive environment for generic and biosimilar medicines. He also outlines the important role the off-patent sector plays in the long-term sustainability of Belgium’s universal healthcare system.…

UAE With the corporate objective of having 75 percent of the company’s revenue coming from international markets by 2020, Laboratoires Expanscience is betting on the Middle East and Africa region. Frédéric Le Moigne, managing director for the MEA region, explains the main challenges presented by the political instability affecting the region,…

Czech Republic Patrik Zachar, Vice President Central Europe of Ipsen, shares how the company has built a strong presence in oncology and neuroscience in the CE region and the Czech Republic, quickly establishing market-leading positions in the indications they compete in. Whilst in neuroscience, Zachar still sees significant growth potential for its…

UAE AKI Investments, under the Alphamed brand, is one of the leading distributors and service providers for the healthcare industry in the Middle East. Doaa Albarbari, COO for AKI’s pharma and consumer business, explains how the company has shied away from being simple “box movers” to become the partner of choice…

Coronavirus The 2019 Wuhan coronavirus outbreak has seen a surge in demand for protective masks as publics across the world seek to protect themselves from infection. Manufacturers of the masks have seen their stocks boom, but supply is outstripping demand and hoarding practices may leave healthcare professionals on the frontline of…

Russia The year 2019, which continued the trend of rapid and numerous changes in healthcare regulations in Russia, was rich with expectations, events and legislative proposals aiming to reform the Russian pharmaceutical industry: medical drugs labeling, reform of price determination, new procedure of entry into drugs civil circulation, amendments to regulatory…

Czech Republic In 1996, Jiří Žák, chairman & current CEO of FARMAK, took over the state-owned producer of vitamins FARMAKON where he previously worked for 30 years and turned it into a flourishing private company focused on the research, development, and production of active pharmaceutical ingredients (APIs), intermediates, and specialized chemicals. Žák shares the early success…

Mexico Below is a selection of top recent news from Mexican pharma and healthcare, including the healthcare reforms president Andres Manuel Lopez Obrador is prioritising, latest news on the INSABI program, cancer research, and the lack of coronavirus expertise in Mexico.   Zero tolerance for corruption: the Mexican pharma sector must…

China Eurasia Group’s Aditya Bhattacharji examines the unfolding coronavirus outbreak, the prospects for China’s political and economic stability, and how healthcare firms should think about the path forward. China appears to be ground zero for a public health experiment with no recent analogues. The situation—in terms of social and economic dislocation—deteriorates…